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Background/aim: The aim of this study was to investigate the effects of PhiKZ phage therapy and meropenem alone or combined
treatments in a pneumonia mouse model induced by the Pseudomonas aeruginosa PAO1 strain. The cross-talk between lungs and
kidneys was also determined.
Materials and methods: The systemic, lung-specific, and kidney-specific inflammation levels and the bacterial load in lung tissue and
biochemical parameters were investigated after PhiKZ phage therapy and meropenem alone or combined treatments in a pneumonia
mouse model induced by the P. aeruginosa PAO1 strain. The cross-talk between lungs and kidneys was also determined by measuring
plasma levels of glycocalyx components.
Results: The greatest reduction in lung bacterial load was obtained with the combined use of the PhiKZ phage and meropenem. The
C-reactive protein level in the patient group was significantly higher than in the treatment groups and decreased after treatment. Serum
interleukin IL-6 levels were statistically significantly higher than in the phage serum and phage + meropenem groups. Pulmonary
infection can trigger proinflammatory cytokines such as IL-6, TNF-α, and IL-1β. Increased cytokines trigger insulin resistance in the
liver. Lung infection triggers liver inflammation because there is communication between the lungs and liver.
Conclusion: Elevated proinflammatory cytokines due to infection were decreased because of the reduced burden of bacterial load after
treatment. This study might have proved communication between lungs and kidneys related to proinflammatory cytokines.
Key Words: Phage therapy, bacterial load, Pseudomonas aeruginosa PAO1, PhiKZ phage, pneumonia, mice model

1. Introduction
Phage therapy is the therapeutic use of bacteriophages to
eliminate or weaken pathogenic bacteria. Phage therapy
has been given reconsideration due to the inadequacy
of antibiotic treatment in the increased numbers of
multidrug-resistant infections (1). The therapeutic use of
phages in the treatment of bacterial infections began in
humans immediately after their discovery (2,3–6). The first
phage therapy study was conducted by d’Herelle in 1919
(7). Despite the declining phage treatment practices in the
world after the discovery of antibiotics, phage treatment
practices continued at the Eliava Institute in Georgia and
the Hirszfeld Institute in Poland (8).
Pseudomonas aeruginosa is a gram-negative, motile,
nonfermentative, aerobic and anaerobic bacterium that
can populate a variety of environments such as soil, water,
plants, and animals (9). P. aeruginosa is an opportunistic
human pathogen that causes chronic and acute infections
* Correspondence: kubra.can@istanbul.edu.tr
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of burn wounds and respiratory and urinary tracts
with significant morbidity and mortality rates (10). In
addition, the major cause of morbidity and mortality in
individuals with cystic fibrosis is P. aeruginosa; it is one
of the main causes of hospital-acquired infections and
lung infections. Moreover, multidrug-resistant rates are
particularly high in P. aeruginosa, which severely limits
the therapeutic options available to treat infected patients
(11). The inadequacy of antibiotics has led physicians to
search for new treatment strategies, one of which is phage
therapy. The PhiKZ phage is a giant bacteriophage in the
family Myoviridae with a circular genome that infects P.
aeruginosa (12). Phages such as PhiKZ are indispensable
components of commercial therapeutic phage mixtures
because of their plentiful growth (13).
Abedon and Thomas-Abedon (2), Abedon et al. (14),
and Abedon (15) revised the use of phage therapy in lung
disease. Morrison and Gardner conducted the first study
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in 1936 (16). They successfully applied local phage therapy
in Bacillus-induced lung disease. The topical treatment of
staphylococcal phage therapy in newborns and children
was investigated in 1938 (17). Sakandelidze and Meipari
treated bronchitis and lung abscesses with subcutaneous
or topical applications of phages (18). Phage therapy uses
a combination of antibiotics and Sulakvelidze et al. (19)
performed polyvalent phage therapy.
P. aeruginosa has been used in phage therapy trials
because it has multidrug resistance and causes a biofilm.
In a study by Wright et al. (20), P. aeruginosa was topically
administered (6 × 105 pfu/mL) to patients with chronic
otitis and was reported to reduce bacterial load. The
successful treatment of infections caused by P. aeruginosa
and Staphylococcus aureus in patient with burns was
done by using phage cocktails (21,22). Yilmaz et al. (23)
used methicillin-resistant Staphylococcus aureus and P.
aeruginosa in rats using an implant-related infection
model. Sb-1 and PAT phages were applied in phage
treatment. The protective usage of ϕMR11 bacteriophages
against Staphylococcus aureus infection in mice was
successfully conducted (24). Phages and combined use
of antibiotics were observed to prevent the formation
of biofilms. Combined usage of phages and antibiotics
effectively reduced the number of bacteria in in vitro and
in vivo experiments (25,26).
Sulakvelidze et al. (19) reviewed phage therapy in
lung diseases. Phages are usually administered topically,
systemically, or orally in the treatment of pulmonary
infections. Topical phage therapy and systemic (parenteral)
administration may be administered individually or
together, and in some cases by direct injection in a rat
model of pulmonary infection (27,28).
The aim of this study was to test the effects of PhiKZ
and meropenem alone or combined treatments in a
pneumonia mouse model induced by the P. aeruginosa
PAO1 strain. For an integrative investigation of the effects
of phage therapy, we measured routine biochemistry
parameters in addition to determining bacterial load in the
lungs. Furthermore, glycocalyx degradation was assessed
by measuring plasma levels of hyaluronan (glycocalyx
compartment), and plasma levels of tumor necrosis factor
(TNF)-α and interleukin (IL)-6 were measured as markers
of inflammation. Moreover, the cross-talk between the
lungs and kidneys was evaluated by measuring cytokines
in kidney tissues.
2. Materials and methods
2.1. Ethical statements and animals
All animal studies were performed in accordance with
the Regulation on Working Procedures and Principles of
Ethical Committees of Animal Experiments (Ministry of
Forestry and Water Management, Turkey, 5199, 2004).

The study was approved by the İstanbul University Animal
Experiments Local Ethics Committee (İÜ HADYEK,
2014/67). Thirty male C57/BL6 mice weighing 21–23 g
were used in this study. The animals were obtained from
İstanbul University’s Institute of Experimental Medicine
(DETAE). Mice were housed under standard laboratory
conditions at DETAE.
2.2. Bacterial and bacteriophage strains and culture
conditions
P. aeruginosa PAO1 (ATCC 15692) and PhiKZ (ATCC
BAA28 B2) phages were purchased from the American
Type Culture Collection (ATCC) and animated and stock
cultures were prepared according to the protocol of the
ATCC. All isolates were stored at –20 °C with 15% glycerol.
2.3. PFU calculation
Phage titer was checked using the double agar overlay
technique of Adams (29) and expressed as plaque forming
units/mL, as previously described by Adams. The P.
aeruginosa PAO1 strain was propagated from a stock
solution. One to two drops of P. aeruginosa PAO1 were add
to 2.5 mL of 0.5% molten agar and mixed and spread in
tryptic soy agar petri dishes. After hardening the overlay,
serial dilutions of 1 mL of phage prepared with 0.9 mL of
TSB and 0.1 mL of phage were poured onto the surface of
each plate. The plate was tilted to ensure the entire surface
was covered. After the surface dried, the petri dishes were
incubated at 37 °C for 24 h. Plaque-forming units (pfu) of
phage were calculated using the following formula:
pfu/mL = number of plaques / d × V.
v = volume of phage added to petri dishes, d = dilution.
2.4. Experimental groups
The mice were divided into 5 groups of 6 individuals.
Experimental groups and their applications are
summarized in the Table. In the pneumonia group, mice
were inoculated intranasally with 10 µL of 5 × 108 cfu/mL
P. aeruginosa PAO1 strain in order to induce a pneumonia
model as previously described in detail by Campodónico
et al. (30). In the control group, mice were inoculated
with phosphate-buffered saline (PBS). In the pneumonia
+ PhiKZ group, mice were inoculated with P. aeruginosa
PAO1 (5 × 108 colony-forming units (cfu)/mL) and phiKZ
phage (1.5 × 108 pfu/mL). In the pneumonia + meropenem
group, mice were inoculated with P. aeruginosa PAO1 (5 ×
108 cfu/mL) and meropenem (100 mg/kg) intraperitoneally.
In the pneumonia + PhiKZ + meropenem group, mice
were inoculated with P. aeruginosa PAO1 (5 × 108 cfu/mL)
and meropenem (100 mg/kg intraperitoneal) and phiKZ
phage (1.5 × 108 pfu/mL).
2.5. Microbiologic and biochemical measurements
Mice were anesthetized using an intraperitoneal injection
of 65 mg/kg ketamine and 13 mg/kg xylazine 24 h after
inoculation. First, bronchoalveolar lavage (BAL) fluid was
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Table. Experimental groups and treatments.
Groups

Inoculation

Treatment 1 (2nd hour)

Treatment 2 (12th hour)

1- Control
(n = 6)

10 µL of sterile PBS

PBS

PBS

2- Pneumonia
(n = 6)

P. aeruginosa PAO1
(5 × 108 cfu/ml)

PBS

PBS

3- Pneumonia +
PhiKZ (n = 6)

P. aeruginosa PAO1
(5 × 108 cfu/mL)

PhiKZ phage (1.5 × 108 pfu/mL)

PhiKZ phage
(1.5 × 108 pfu/mL)

4- Pneumonia +
meropenem (n = 6)

P. aeruginosa PAO1
(5 × 108 cfu/mL)

Meropenem
(100 mg/kg intraperitoneal)

Meropenem
(100 mg/kg intraperitoneal)

5- Pneumonia +
PhiKZ + meropenem (n = 6)

P. aeruginosa PAO1
(5 × 108 cfu/mL)

PhiKZ phage (1.5 × 108 pfu/mL) +
meropenem (100 mg/kg intraperitoneal)

PhiKZ phage (1.5 × 108 pfu/mL) +
meropenem (100 mg/kg intraperitoneal)

taken under anesthesia. A left main bronchial catheter was
placed and washed with 1 mL of isotonic NaCl solution. In
each wash, the solution was rapidly injected and collected
slowly. After the bronchoalveolar lavage fluid was taken,
blood was taken from the heart. Entering the heart with
a 1-mL syringe and with all the blood taken in one shot,
the animals were sacrificed and the kidney and lung
tissues were taken for histopathological and biochemical
examination. Lungs and kidneys were harvested and blood
samples was centrifuged at 5000 rpm for 7 min at 4 °C.
After removal of erythrocytes, plasma samples were stored
with kidney samples at –80 °C until measurement day.
Lung samples were immediately used for bacterial load
measurement.					
2.6. Determination of bacterial load
Homogenized lung tissues were centrifuged at 1400× g for
10 min. The supernatant was collected and serially diluted
to 106. One hundred microliters of diluted samples were
plated onto Muller-Hinton agar. Bacteria colonies were
counted after 24 h of incubation at 37 °C. Colony-forming
units (cfu) were determined using the formula:
Z
Cs=
×Vs
Vtot
Cs: Estimated number of cfu.
Z: Total number of colonies.
Vs: Selected reference volume (1 mL or 100 mL).
Vtot: Collected amount of colonies from dilution
counted from petri dishes.
2.7. Biochemical measurements
C-reactive protein (CRP), alanine aminotransferase
(ALT), aspartate aminotransferase (AST), urea, glucose,
lactate, and creatinine levels were determined as routine
biochemical measurements. Plasma levels of IL-6, IL1β, and TNF-α were measured using an enzyme-linked
immunosorbent assay (ELISA) as markers of systemic and
tissue inflammation (e-BioScience, USA) following the
directions of the kit’s manufacturer and concentrations
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were measured at 405 nm as absorbance. Hyaluronan
is the main component of endothelial glycocalyx, in the
extracellular matrix, and alterations in its concentration
in plasma can be attributed to glycocalyx volume loss.
Hyaluronan concentrations were determined using
the Sun Red hyaluronic acid test kit (Sun Red, China),
which is based on an enzyme-linked hyaluronic acid
binding protein assay. The kit’s procedure was applied
and the absorbance values were measured at
 405 nm.
Lung homogenate protein content was quantified using
Bradford’s assay (Bio-Rad, USA).
2.8. Statistics
Datasets are presented as means ± SEM and were analyzed
using GraphPad Prism 5.0 (GraphPad Software, La Jolla,
CA, USA). Groups were compared using one-way analysis
of variance and, when appropriate, post hoc analyses with
Tukey tests. Statistical significance was considered as P <
0.05.
3. Results
3.1. Bacterial load
Bacterial load was measured from homogenized lung
tissues through the recovery of PAO1 (Figure 1A). The
bacterial load of the pneumonia group was 5.82 ± 0.07
log P. aeruginosa PAO1. The bacterial load of the group
treated with PhiKZ was 4.4 ± 0.14 log. The bacterial
load of the meropenem and meropenem + PhiKZ
treatment groups were 4.84 ± 0.08 log and 4.33 ± 0.03 log,
respectively. Bacterial load was reduced by about 89% in
the PhiKZ treatment group. Bacterial load reduction of the
meropenem and meropenem + PhiKZ treatment groups
was 96% and 97%, respectively. Statistically significant
bacterial load reduction (P < 0.05) was observed in the
treatment groups (Figure 1A).
3.2. Routine biochemical results
Measurements of CRP, ALT, AST, urea, glucose, lactate,
and creatinine levels were performed (Figures 1B–1D).
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Figure 1. Bacterial load and biochemical measurements: A) bacterial load in lung homogenate, B) lactate, C) CRP, D) glucose.

CRP level (Figure 1C) was found statistically significant
at 0.92 ± 0.3 mg/L in the pneumonia group (P < 0.05 vs.
control). CRP levels of the phage, meropenem, and phage
+ meropenem groups were lower than in the pneumonia
group. The glucose level of the pneumonia group
(Figure 1D) was determined as 300.4 ± 89.5 mg/L and a
statistically significant difference was found between the
pneumonia and treatment groups (P < 0.05). The lactate
measurements (Figure 1B) showed the highest mean value
in the pneumonia group (8.3 ± 1.2 mmol/L) and the lowest
mean value in the control group (3.03 ± 0.8) (P < 0.05,

pneumonia vs. control group). When ALT, AST, urea,
and creatinine levels were investigated in serum samples,
no statistically significant difference was found between
pneumonia and the other treatment groups.
3.3. Inflammatory and glycocalyx degradation products
ELISA results are presented in Figures 2A–2D. There was
a significant difference between IL-6 values (Figure 2D) in
the control and pneumonia groups (P < 0.05). In addition,
posttreatment IL-6 levels showed a statistically significant
decrease (P < 0.01). In the phage treatment group, the
level of IL-6 was measured as 306.8 ± 67.1 pg/mL and
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Figure 2. ELISA results: A) TNF-α levels of kidney homogenate, B) hyaluronan levels of sera, C) IL-6 levels of BAL, D) IL-6 levels of sera.

was found to be lowest compared to other treatment
groups. Serum IL-1β levels were measured highest in
the pneumonia group (24.38 ± 15.6 pg/mL) and lowest
(8.578 ± 1.3 pg/mL) in the phage + meropenem group. IL1β levels were decreased in all treatment groups, but no
statistically significant difference was found. The highest
TNF-α level was measured in the pneumonia group as
13,630 ± 9509 pg/mL. In the treatment groups, the lowest
value obtained was 1245 ± 1102 pg/mL in the phage
+ meropenem treatment group. A decrease in TNF-α
levels (Figure 2A) was observed in the treatment groups.
Hyaluronan measurements (Figure 2B) in serum samples
were 1469 ± 157 ng/mL in samples from the pneumonia
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group. In the phage-treated group, it was 952 ± 123.0 ng/
mL, which was the lowest among the groups. A statistically
significant decrease was observed between the control and
pneumonia groups (P < 0.05).
3.4. Measures related to the inflammatory process and
glycocalyx in BAL
In IL-6 measurements (Figure 2C) performed on BAL
samples, the highest value was measured as 26,485 ± 19,242
pg/mL in samples from the pneumonia group. The mean
IL-6 level was measured as 6574 pg/mL in the treatment
groups. The value in the pneumonia group was statistically
higher than in the control group (P < 0.05, t-test). Levels of
IL-1β were 1319 ± 769 pg/mL in the pneumonia group and
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130.7 ± 68 pg/mL in the control group. The levels of IL1β in the control and treatment groups were significantly
lower than in the pneumonia group; however, this was not
statistically significant.
The highest value (1261 pg/mL) was found in samples
from the pneumonia group in the TNF-α assay in BAL
samples. The mean TNF-α value in the treatment groups
was 340 pg/mL. There was a decrease in the TNF-α value
in the treatment groups compared with the pneumonia
group, but no statistically significant difference was found.
3.5. Measures Related to the inflammatory process and
glycocalyx in the kidneys
The average IL-6 level in samples from the pneumonia
group was 4115 ± 882 pg/mL. In the control samples, it
was 1163 ± 1115 pg/mL. The mean value in the treatment
groups was found as 2268 pg/mL. There was a significant
difference between the pneumonia group and the group
treated with meropenem (P < 0.05). IL-1β was found as
1113 ± 363 pg/mL in samples from the pneumonia group
and 255 pg/mL in the treatment groups. There was no
statistically significant difference between the groups. The
mean TNF-α level in samples from the pneumonia group
was 756.8 ± 49.6 pg/mL. In the treatment groups, there
was a decrease (254 pg/mL) according to the pneumonia
group. There was a statistically significant difference
between the control group and the patient group (P <
0.05). The mean hyaluronan value of the pneumonia group
was 152.7±16.5 ng/mL. The mean value in the treatment
groups was 132.7 ng/mL.
4. Discussion
P. aeruginosa is one of the main causes of hospital-acquired
infections with a high rate of morbidity and mortality. It is
also an opportunistic pathogen that can lead to bacterial
infection in patients who are immunocompromised
(cancer, HIV, cystic fibrosis, burn infections). Treatments
are difficult because of natural antibiotic resistance
mechanisms. Experimental studies have been carried out
in recent years on the use of phages in the treatment of
lung infections caused by P. aeruginosa (31).
Bacterial load reduction was about 89% in the PhiKZ
treatment group, and 96% (P < 0.05) and 97% (P < 0.05)
bacterial load reductions were observed in the meropenem
and meropenem + PhiKZ treatment groups, respectively.
A significant reduction in bacterial load was obtained in
the lungs in the treatment groups. A statistically significant
difference (P < 0.05) was observed between the pneumonia
group and other groups. Combined treatment of phage +
meropenem was found as the most effective treatment
against P. aeruginosa pneumonia in this mouse model.
In this study, serum CRP, lactate, and hyaluronan
levels between the pneumonia and control groups were
statistically significant. A significant reduction in bacterial

load was obtained in the lungs in the treatment groups.
The IL-6 level (P < 0.05, t-test) in BAL samples showed a
statistically significant difference between the pneumonia
group and control group. There were statistically significant
differences in renal homogenates between the pneumonia
and control groups in levels of IL-6 (P < 0.05) and TNF-α
(P < 0.05).
Alemayehu et al. (32) used φMR299-2 and φNH-4
phages to eliminate P. aeruginosa in the mouse lung and
cystic fibrosis lung cells. They found a 3–4 log decrease
in bacterial load within 6 h. In our study, a decrease
of 1.5 log was observed. Pires et al. (31) used phages in
biofilm treatment and observed a significant decline
after 6 h. Torres-Barceló et al. (33) used a phage and
antibiotic combination against P. aeruginosa, similar to
this study. They reported that combined therapy was
more effective than the phage alone or antibiotics alone.
Their result is consistent with the results of the present
study. Phage therapy and antibiotics affect the bacterium
through different mechanisms; therefore, combined
treatment reduces resistance formation and can be used
against pathogens with high resistance (34,33). A better
understanding of the pharmacodynamics of combined
therapy will allow the identification of new treatment
strategies in multiresistant bacterial infections. The YH6
phage was used as an alternative phage therapy agent
against multidrug-resistant P. aeruginosa in a murine
haemorrhagic pneumonia model (35).
PAK-P and P3-CHA phages were also tested in a
multidrug-resistant P. aeruginosa mouse pneumonia
model for treatment, and decreases of mortality rate and
bacterial load after 18 h of treatment were observed (36).
Debarbieux et al. (37) observed a decrease in mortality
and lung inflammation as a result of treatment with the
PAK-P1 phage in a P. aeruginosa mouse pneumonia model.
Combined treatment with LUZ7 phage and streptomycin
was administered against nosocomial pathogen P.
aeruginosa. Coadministration of the phage and antibiotics
led to a stronger reduction in bacterial count than the
phage or antibiotic treatment alone; moreover, unlike
single therapies, after combined treatment, the bacteria
did not reach their old levels.
In our study, the greatest decrease in bacterial count
was observed in the combined administration of the phage
and meropenem (97% decrease, P < 0.05). Similarly, the
use of antibiotics caused a decrease in the number of
bacteria, and the SBWu2 phage alone reduced the number
of bacteria. However, the combined use of the phage and
antibiotics caused the greatest decrease (38). It was also
reported that bacterial resistance formation was less with
the combined treatment (38). Verma et al. (39) studied the
efficacy of cefloxacin and phage treatment in vitro using
Klebsiella pneumoniae biofilm. Although antibiotic alone
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has therapeutic efficacy, biofilm-forming bacteria include
very resistant strains. Less resistant strains are formed after
combined treatment. A highly synergistic effect of an antiPseudomonas phage cocktail combined with ciprofloxacin
against P. aeruginosa was found (40). In conclusion, it has
been shown in the present study that combined treatment
eliminates biofilms and prevents the formation of resistant
strains.
In our study, in the serum samples, the CRP level in
the patient group was found significantly higher (P <
0.05) than in the treatment groups and it decreased after
treatment. In the study by Majhi et al. (41), combined
antibiotic treatment (levofloxacin and ceftriaxone) was
applied in a pneumonia model caused by Streptococcus
pneumoniae in BALB/c mice. The serum CRP level (P
< 0.05) was decreased 24 h after treatment. The authors
suggested that the reduction of bacterial burden in the
lungs caused a decrease in CRP levels after treatment.
These results support our findings.
Monitoring of lactate is an important marker in
pneumonia. In our study, the lactate level in serum
samples of the pneumonia group increased significantly (P
< 0.05) compared with the control group; the high lactate
level decreased after treatment. Lactate level in serum was
elevated in patients with pneumonia and rapidly decreased
to normal levels in 12–24 h of treatment (42).
In this study, a significant decrease (P < 0.05) in IL-6
levels in serum samples was observed in the treated groups
compared with the patient group. Zimecki et al. (43)
reported decreased IL-6 in serum after phage treatment (S.
aureus A5/L) in a pneumonia mouse model. In their study,
Matsuda et al. (44) produced peritoneal models in mice
and treated them with lysine mutant phages. As a result
of the treatment, there was a significant decrease in serum
IL-6 level. A combination of levofloxacin and ceftriaxone
was used in the treatment of lung inflammation in the
mouse model, and similarly, a decrease in serum IL-6
levels was observed (41).
Debarbieux et al. (37) reported that levels of TNF-α
and IL-6 in BAL samples were lowered as a result of phage
treatment. Hung et al. (45) performed successful treatment
with the φNK5 phage in a liver abscess caused by Klebsiella
pneumoniae. After treatment, serum TNF-α and IL-6
levels were significantly decreased, and bacterial load was
decreased in the blood. Although AST and ALT levels
increased after infection, no change was observed in the
phage treatment group. There was no significant difference
in ALT and AST values. AST and ALT levels were elevated
due to insufficient liver function after infection (45). P.
aeruginosa may have had less load on the liver than in
other studies because there was no significant increase in
AST and ALT in our study.
Serum IL-6 levels were 338.6 pg/mL in the phage
treatment group and 184.1 pg/mL in the control group.
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IL-6 levels were found statistically significantly higher
than in phage serum (t-test, P < 0.0001) and the phage +
meropenem group (t-test, P < 0.007). Endotoxins released
from gram-negative bacteria after phage treatment may
increase the production of TNF-α and IL-6 (46,47). High
phage concentration and prolonged exposure to phages
can increase the proinflammatory response.
Pulmonary inflammation can cause secondary
infections in other organs such as the kidneys. Si et al. (48)
developed a model of acute respiratory distress syndrome
by injecting tracheal lipopolysaccharide into mice and
investigated kidney damage as a secondary infection. Poly
polymerase (PARP) binds to the ADP-ribose of target
proteins, changes chromatin structure and transcription
regimes, and increases DNA damage. Excessive amounts
of active PARP may trigger an immunologic response. It
also leads to NF-κB activation, which leads to an increase
in inflammatory cytokines.
The mean TNF-α level in kidney samples of the
pneumonia group was 756.8 ± 49.6 pg/mL. In the
treatment groups, the TNF-α level was decreased (254
pg/mL) and there was a statistically significant difference
between the control group and the pneumonia group (P
< 0.05). The mean hyaluronan value of the pneumonia
group was 152.7 ± 16.5 ng/mL and the mean value in
the treatment groups dropped to 132.7 ng/mL. The
serum creatinine level was also elevated in the study as
an indication of renal dysfunction. This study might
have proved that communication between the lungs and
kidneys is related to proinflammatory cytokines.
Pulmonary infections can trigger proinflammatory
cytokines such as IL-6, TNF-α, and IL-1β. Increased
cytokines trigger insulin resistance in the liver. IL-6 and
TNF-α most likely reduce the effect of intestinal insulin,
reduce glucose uptake, and thus increase the level of
blood glucose. Lung infections trigger liver inflammation
because there is communication between the lung and
the liver. In this study, the serum lactate level increased
with infection. Increased lactate enters the liver tissue,
triggering glucose production, which can increase serum
glucose levels.
The greatest reduction in lung bacterial load was
obtained by the combined use of the PhiKZ phage and
meropenem. Elevated proinflammatory cytokines due
to infection decreased through the reduced burden of
bacterial load after treatment. The level of hyaluronan,
a sign of lung injury in pneumonia, was significantly
higher in the patient group. The increase in IL-6 and
TNF-α levels in kidney tissue suggests that there was an
interaction between the lungs and the kidneys. Elevation
of serum lactate and glucose values suggests that the same
interaction may occur with the liver. We believe that this
work will encourage and guide new studies on phage
therapy.
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